Literature DB >> 11107089

Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease.

M M McDermott1, M H Criqui, K Liu, J M Guralnik, P Greenland, G J Martin, W Pearce.   

Abstract

OBJECTIVE: We compared three commonly used methods of ankle/brachial index (ABI) calculation to determine their relative association with objective measures of leg functioning in peripheral arterial disease.
METHOD: The study design was cross-sectional; the setting was an academic medical center. The participants were 244 men and women, aged 55 years and older, with and without peripheral arterial disease, from a noninvasive vascular laboratory and a general medicine practice. The main outcome measures were walking velocity and endurance, measured with the 4-m walk and the 6-minute walk, respectively. Three methods of ABI calculation were assessed: using the highest arterial pressure within each leg (method #1), using the lowest pressure in each leg (method #2), and averaging the dorsalis pedis and posterior tibial pressures within each leg (method #3). For each method, we established the prevalence of peripheral arterial disease. We then used regression analyses to identify the ABI calculation method most closely associated with leg functioning. The ABI with the greatest statistical significance and largest regression coefficient was considered most closely associated with leg functioning.
RESULTS: Peripheral arterial disease prevalence ranged from 47% when method #1 was used to 59% when method #2 was used. When the right and left legs were compared, the leg with the lower ABI, as identified through use of method #3, was most associated with leg functioning. Within the leg with the lower ABI, method #3 was more closely associated with 6-minute walk distance (regression coefficient = 811.5 feet per 1 unit ABI; P<.001) and 4-m walking velocity (regression coefficient = 0.353 m/s per 1 unit ABI; P<.001) than method #1 or method #2.
CONCLUSION: The lower ABI, determined by averaging the dorsalis pedis and posterior tibial arterial pressures in each leg, is most predictive of walking endurance and walking velocity in peripheral arterial disease.

Entities:  

Mesh:

Year:  2000        PMID: 11107089     DOI: 10.1067/mva.2000.108640

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  103 in total

1.  Greater sedentary hours and slower walking speed outside the home predict faster declines in functioning and adverse calf muscle changes in peripheral arterial disease.

Authors:  Mary M McDermott; Kiang Liu; Luigi Ferrucci; Lu Tian; Jack M Guralnik; Yihua Liao; Michael H Criqui
Journal:  J Am Coll Cardiol       Date:  2011-06-07       Impact factor: 24.094

2.  Peripheral artery disease, calf skeletal muscle mitochondrial DNA copy number, and functional performance.

Authors:  Mary M McDermott; Charlotte A Peterson; Robert Sufit; Luigi Ferrucci; Jack M Guralnik; Melina R Kibbe; Tamar S Polonsky; Lu Tian; Michael H Criqui; Lihui Zhao; James H Stein; Lingyu Li; Christiaan Leeuwenburgh
Journal:  Vasc Med       Date:  2018-05-08       Impact factor: 3.239

3.  Ankle Brachial Pressure Index: identifying cardiovascular risk and improving diagnostic accuracy.

Authors:  N Bhasin; D J A Scott
Journal:  J R Soc Med       Date:  2007-01       Impact factor: 5.344

4.  Wall morphology, blood flow and wall shear stress: MR findings in patients with peripheral artery disease.

Authors:  Mauricio S Galizia; Alex Barker; Yihua Liao; Jeremy Collins; James Carr; Mary M McDermott; Michael Markl
Journal:  Eur Radiol       Date:  2013-12-11       Impact factor: 5.315

5.  Baseline functional performance predicts the rate of mobility loss in persons with peripheral arterial disease.

Authors:  Mary M McDermott; Jack M Guralnik; Lu Tian; Luigi Ferrucci; Kiang Liu; Yihua Liao; Michael H Criqui
Journal:  J Am Coll Cardiol       Date:  2007-08-20       Impact factor: 24.094

6.  Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease.

Authors:  Mary M McDermott; Luigi Ferrucci; Jack M Guralnik; Lu Tian; David Green; Kiang Liu; Jin Tan; Yihua Liao; William H Pearce; Joseph R Schneider; Paul Ridker; Nader Rifai; Frederick Hoff; Michael H Criqui
Journal:  J Am Coll Cardiol       Date:  2007-08-13       Impact factor: 24.094

7.  Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study).

Authors:  Mary M McDermott; Jack M Guralnik; Lu Tian; Kiang Liu; Luigi Ferrucci; Yihua Liao; Leena Sharma; Michael H Criqui
Journal:  J Am Coll Cardiol       Date:  2009-03-24       Impact factor: 24.094

8.  Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial.

Authors:  Mary M McDermott; Philip Ades; Jack M Guralnik; Alan Dyer; Luigi Ferrucci; Kiang Liu; Miriam Nelson; Donald Lloyd-Jones; Linda Van Horn; Daniel Garside; Melina Kibbe; Kathryn Domanchuk; James H Stein; Yihua Liao; Huimin Tao; David Green; William H Pearce; Joseph R Schneider; David McPherson; Susan T Laing; Walter J McCarthy; Adhir Shroff; Michael H Criqui
Journal:  JAMA       Date:  2009-01-14       Impact factor: 56.272

9.  Circulating blood markers and functional impairment in peripheral arterial disease.

Authors:  Mary M McDermott; Kiang Liu; Luigi Ferrucci; Lu Tian; Jack M Guralnik; David Green; Jin Tan; Yihua Liao; William H Pearce; Joseph R Schneider; Kimberly McCue; Paul Ridker; Nader Rifai; Michael H Criqui
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

Review 10.  Ankle brachial index for the diagnosis of lower limb peripheral arterial disease.

Authors:  Fay Crawford; Karen Welch; Alina Andras; Francesca M Chappell
Journal:  Cochrane Database Syst Rev       Date:  2016-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.